Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
On Wednesday, June 11th, Dr. James Cox, ATS Medical Director, will presentthe "History of Arrhythmia Surgery: Lessons Learned from Surgical Extinction".The ATS CryoMaze(TM) Surgical Ablation System is proven to yield clinicalresults similar to the conventional cut-and-sew Cox Maze III procedure for thesurgical ablation of atrial fibrillation and will be the focus of severaladditional scientific presentations. On June 11th, Dr. Evilio Rodriguez ofEast Carolina Medical Center will present the "Cryo-Maze Procedure." OnFriday, June 13th, Dr. Harold Roberts of Florida Medical Center will presenthis unique procedure the "Robotic Endoscopic Cox-Cryomaze: A MinimallyInvasive Cure of Continuous Atrial Fibrillation." Dr. Roberts will expand onthe clinical benefits of the ATS CryoMaze procedure in a poster session titled"Short-Term Outcomes Confirm the Effectiveness and Safety of Cryomaze inPatients Undergoing Concomitant Cardiac Surgeries." These presentations speakto the expansion of cryoablation into minimal access and stand-alone surgicalprocedures for the treatment of atrial fibrillation that can improve efficacywhile reducing the risk profile.
Advertisement
The ATS 3f Enable(R) Aortic Bioprosthesis is currently in clinical trialsin Europe and is designed to eliminate the traditional suturing now requiredwhen replacing a patient's diseased or degenerated aortic heart valve. OnThursday, June 12th, Professor Thierry Carrel, from Bern, Switzerland, willpresent "Sutureless Valves: Design, Implantation Technique and Early ClinicalResult" and Professor Sven Martens, from Frankfurt, Germany will present"Single Center Experience with the ATS Enable Bioprosthesis." Both willdemonstrate the excellent early clinical outcomes with regard to bothimplantation and valve performance.
Michael D. Dale, Chairman, President and CEO of ATS Medical noted, "We arevery gratified that ATS Medical products will be the focus of a variety of keypresentations at this year's ISMICS meeting. It illustrates that ourstrategic plan to expand into bioprostheses, cryotherapy and minimallyinvasive approaches has well positioned us in technologies that areinnovative, forward thinking and of great interest to cardiac surgeons. ATSMedical continues to gain recognition as a prominent entity in these marketsegments and we look forward to introducing product innovations that allowsurgeons to advance the standard of care for their patients."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused oncardiac surgery. The Company, global in scope, is headquartered inMinneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves,which utilize a unique pivot design resulting in exceptional performance andlow risk profile, have been implanted in patients worldwide. The ATS 3f(R)brand encompasses multiple tissue heart valve product offerings at varyingsteps from market introductions to clinical trials to development projectsthat incorporate less invasive valve replacement technology. ATS Medical'sfocus on serving the cardiac surgery community is further strengthened byofferings that include ATS Simulus(R) annuloplasty products for heart valverepair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical website is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may includestatements regarding intent
